Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis

BACKGROUND AND PURPOSE: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015-2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. RESULTS: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578-616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20-1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97-1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34-1.78). INTERPRETATION: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.

Authors

Institutions

Publication Details

Journal
Acta Oncologica
Published
2026-11-18
DOI
https://doi.org/10.2340/1651-226x.2026.46522
Primary Topic
Economic and Financial Impacts of Cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis

Peter M. Strang, Lars‐Åke Levin, Torbjörn Schultz, Giovanni Galvis
1 links
Acta Oncologica
Economic and Financial Impacts of Cancer
article

Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis

Peter M. Strang, Lars‐Åke Levin, Torbjörn Schultz, Giovanni Galvis
article en

Abstract

BACKGROUND AND PURPOSE: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015-2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. RESULTS: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578-616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20-1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97-1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34-1.78). INTERPRETATION: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.

Acta OncologicaVol. 65
Linköping University (SE), Karolinska Institutet (SE)
Good health and well-being
Economic and Financial Impacts of Cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon